新生儿危重与非危重主动脉瓣狭窄的结局:回顾性队列研究
该全国性回顾性队列研究纳入瑞典1994–2018年所有因孤立性主动脉瓣狭窄治疗的新生儿,比较危重与非危重患儿的长期生存、再干预及危险因素。危重组30天无死亡,长期无移植生存率91%对98%(p=0.134),无事件生存率40%对67%(p=0.002),再干预中位时间3.6个月对3.9年(p=0.008),危重组再干预需求更高。
要点
- 危重主动脉瓣狭窄定义:瓣膜狭窄伴导管依赖体循环或左室功能减低(缩短分数≤27%)。
- 非危重主动脉瓣狭窄治疗指征:多普勒平均压差>50 mmHg。
- 危重组无事件生存率显著低于非危重组,再干预中位时间更早(3.6个月对3.9年)。
核心结论
- 危重主动脉瓣狭窄新生儿在生后第一年再干预需求显著更高,无事件生存率更低。
- 危重组18岁及以上免于主动脉瓣置换的比例更低。
研究设计与样本
- 全国性回顾性队列研究,使用患者病历、超声心动图和瑞典国家人口登记数据。
- 纳入瑞典1994–2018年所有因孤立性主动脉瓣狭窄治疗的新生儿。
- 危重主动脉瓣狭窄65例,非危重主动脉瓣狭窄42例;中位随访13.5年,无失访。
主要发现
- 30天死亡率为零。
- 长期无移植生存率危重组91%,非危重组98%(p=0.134)。
- 无事件生存率危重组40%,非危重组67%(p=0.002)。
- 从初始治疗到再干预的中位时间危重组3.6个月,非危重组3.9年(p=0.008)。
- 大多数新生儿接受外科瓣膜切开术治疗。
关键数值与推荐
- 危重主动脉瓣狭窄判定标准:瓣膜狭窄伴导管依赖体循环或左室功能减低(缩短分数≤27%)。
- 非危重主动脉瓣狭窄治疗指征:多普勒平均压差>50 mmHg。
临床怎么用
- 对危重主动脉瓣狭窄新生儿应预期生后第一年内高再干预风险并加强随访。
- 非危重主动脉瓣狭窄患儿再干预时间较晚,但仍需长期监测无事件生存。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare long-term survival, reinterventions and risk factors using strict definitions of neonatal critical and non-critical valvular aortic stenosis (VAS). DESIGN: A nationwide retrospective study using data from patient files, echocardiograms and the Swedish National Population Registry. SETTING AND PATIENTS: All neonates in Sweden treated for isolated VAS 1994-2018. We applied the following criteria for critical aortic stenosis: valvular stenosis with duct-dependent systemic circulation or depressed left ventricular function (fractional shortening ≤27%). Indication for treatment of non-critical VAS was Doppler mean gradient >50 mm Hg. MAIN OUTCOME MEASURES: Short-term and long-term survival, aortic valve reinterventions need of valve replacements, risk factors for reintervention and event-free survival. RESULTS: We identified 65 patients with critical VAS and 42 with non-critical VAS. The majority of the neonates were managed by surgical valvotomy. Median follow-up time was 13.5 years, with no patients lost to follow-up. There was no 30-day mortality. Long-term transplant-free survival was 91% in the critical stenosis group and 98% in the non-critical stenosis group (p=0.134). Event-free survival was 40% versus 67% (p=0.002) in the respective groups. Median time from the initial treatment to reintervention was 3.6 months versus 3.9 years, respectively (p=0.008). CONCLUSIONS: Critical VAS patients had significantly higher need for reintervention during the first year of life, lower event-free survival and lower freedom from aortic valve replacement at age ≥18 years, compared with neonates with non-critical stenosis.
引用
- Olofsson CK, Hanseus K, Ramgren JJ, et al. Outcomes in neonatal critical and non-critical aortic stenosis: a retrospective cohort study. Arch Dis Child. 2023. PMID: 36657799. doi:10.1136/archdischild-2022-324189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。